Plasminogen/Plasmin Inhibitor
-
6-Aminocaproic acid
0 ImagesSynonyms: EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.
-
JTV-803
0 ImagesCat. No.: HY-187960CAS No.: 247131-06-2JTV-803 is a selective and competitive direct factor Xa (FXa) inhibitor with a Ki of 19 nM and an IC50 of 81 nM against human FXa, and its action is independent of antithrombin III (ATIII). JTV-803 exhibits significantly higher selectivity for human FXa than for thrombin, plasmin, and trypsin. JTV-803 produces sustained ex vivo anti-FXa inhibitory activity in vivo. JTV-803 prolongs aPTT and PT, prevents dialyzer thrombosis, and is cleared during dialysis. JTV-803 dose-dependently attenuates coagulation activation, maintains plasma ATIII activity, reduces glomerular fibrin deposition, and improves survival rate. JTV-803 can be used for research related to thrombosis and hemodialysis anticoagulation.
-
Pexamsiran sodium
0 ImagesCat. No.: HY-185319APexamsiran sodium is a siRNA that inhibits plasminogen synthesis reducer, and can be use for the study of hereditary haemorrhagic telangiectasia.
-
2-O-(2,4,6-Trihydroxyphenyl)-6,6'-bieckol
0 ImagesCat. No.: HY-N18088CAS No.: 89079-38-92-O-(2,4,6-Trihydroxyphenyl)-6,6'-bieckol is a bisphenol compound and a serine protease inhibitor. 2-O-(2,4,6-Trihydroxyphenyl)-6,6'-bieckol exhibits inhibitory activities against α2-macroglobulin, α2-plasmin inhibitor and plasmin, with corresponding IC50 values of 1.9 μg/mL, 0.7 μg/mL and 13 μg/mL.
-
KLK6-IN-1
0 ImagesCat. No.: HY-182600CAS No.: 2370980-52-0KLK6-IN-1 is a reversible small‑molecule inhibitor of KLK6, KLK1, and plasmin. KLK6-IN-1 shows IC50 values of 1.57 μM (KLK6), 5.1 μM (KLK1), 7.4 μM (plasmin), and Ki values of 0.8 μM (KLK6), 2.4 μM (KLK1), 1.3 μM (plasmin). KLK6-IN-1 is highly selective for KLK6 and its proteolytic network. KLK6-IN-1 induces oligodendrocyte differentiation by promoting oligodendrocyte precursor cell maturation. KLK6-IN-1 can be used for the research of multiple sclerosis.
-
Pexamsiran
0 ImagesCat. No.: HY-185319CAS No.: 3056860-75-1Pexamsiran is a siRNA that inhibits plasminogen synthesis, and can be use for the study of hereditary haemorrhagic telangiectasia.
-
PSI-112
0 ImagesCat. No.: HY-182565CAS No.: 1854997-77-5PSI-112 is a YO-class μPlm inhibitor, with IC50 values of 0.38 μM, 1.48 μM and 0.37 μM against the wild-type, F587A mutant and K607A mutant, respectively. PSI-112 shows low affinity for uPA. PSI-112 can be used in cancer research.
-
Pefabloc PL
0 ImagesCat. No.: HY-183860CAS No.: 2131171-67-8Pefabloc PL is a plasmin inhibitor with submicromolar-range inhibitory activity against the trypsin-like serine protease plasmin.
-
GYKI-14451 sulfate
0 ImagesCat. No.: HY-111318CAS No.: 83861-29-4GYKI-14451 sulfate is an inhibitor of thrombin and plasmin. GYKI-14451 sulfate inhibits thrombin-fibrinogen and plasmin-fibrin reactions. GYKI-14451 sulfate inhibits fibrin clot lysis and prolongs fibrin clot lysis time in a dose-dependent manner. GYKI-14451 sulfate does not undergo N-terminal cyclization and spontaneous inactivation in neutral aqueous buffer. GYKI-14451 sulfate can be used in studies related to venous thrombosis and fibrinogen solidification.
